openPR Logo
Press release

ENCITE Symposium ”Red hot MRI: In vivo 19F imaging” Towards clinical application

11-29-2012 07:56 PM CET | Health & Medicine

Press release from: EIBIR GmbH

Press Article Nijmegen

Press Article Nijmegen

Nijmegen, The Netherlands, October 29, 2012: The European Network for Cell Imaging and Tracking Expertise (ENCITE) held a 2-day symposium at the Radboud University Nijmegen Medical Centre (NL) on October 25-26, 2012 on the emerging technique of fluorine (19F) Magnetic Resonance Imaging (MRI), titled "Red hot MRI: In vivo 19F imaging".

19F MRI is uniquely applicable to areas such as cell tracking. This has yet to be applied in the clinic, although clinical trials are ongoing. The field has made tremendous progress since its first demonstration in 2005, in a paper in Nature Biotechnology. Since that time, several research groups throughout Europe have been working on this issue. In particular, the following research organisations within the ENCITE consortium have been closely collaborating on this for three years now: Max-Planck-Institute for neurological science (DE), Westfälische Wilhelmsuniversität Münster (DE), Katholieke Universiteit Leuven (BE), Leiden University Medical Center (NL) and Erasmus MC (NL). Thus, this symposium was organised to bring together researchers interested in 19F MRI, and provide an informal platform for discussing the technique and problems encountered.

The first day of the meeting was open to all scientists, and the second was for ENCITE members only. This was the first meeting of its kind in the Netherlands. The programme included invited keynote talks and abstract presentations. A wide range of topics were presented, such as chemical syntheses of novel probes, design and optimisation of imaging sequences, cell labelling and hardware development.
In total, more than 50 registrants and 15 abstract submissions were received from Europe, mainly from The Netherlands, Germany, Belgium and Italy. Abstracts were received from both academia and industry. The format of the meeting allowed plenty of time for questions and answers as well as fruitful discussions, and the participants responded enthusiastically. The symposium was endorsed by the European Society of Magnetic Resonance in Medicine and Biology (ESMRMB).

Due to the success of the meeting, it is planned to organise this workshop on a regular basis.

Details on the latest news: www.encite.org

For further information on the project please contact:
European Institute for Biomedical Imaging Research (EIBIR), Project Coordination
Neutorgasse 9, 1010 Vienna (AT)
Phone: +43-1-5334064-20 / office@eibir.org / www.eibir.org, www.encite.org

Scientific Coordinator: Prof. Gabriel P. Krestin, ERASMUS MC, ehaas@eibir.org
###

EIBIR - European Institute for Biomedical Imaging Research
Website: www.eibir.org
Contact: office@eibir.org

EIBIR gemeinnützige GmbH
zur Förderung der Erforschung der biomedizinischen Bildgebung
Neutorgasse 9, 1010 Vienna, Austria
T +43 1 533 40 64-20, F +43 1 535 70 41
www.eibir.org
office@eibir.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release ENCITE Symposium ”Red hot MRI: In vivo 19F imaging” Towards clinical application here

News-ID: 244239 • Views:

More Releases from EIBIR GmbH

Living cells as an
Living cells as an "active drug" Advances in image-guided cell therapy promise b …
Leiden, Austria, November 19, 2012 - A video showcasing how in vivo image-guided cell therapy is revolutionising medicine and describing ENCITE’s strong contribution to this revolution has been launched at the ENCITE’s workshop “on cell imaging and tracking: now and the future” at the Leiden University Medical Centre/NL on November 5, 2012. For three patients, each affected by one of today’s major health care problems – diabetes, cancer and cardiovascular disease
ENCITE hands-on workshop “Cell tracking with MRI“ The method of choice for preclinical investigations of revealing cell dynamics in vivo
ENCITE hands-on workshop “Cell tracking with MRI“ The method of choice for p …
Cologne, Germany, November 14, 2012: Within the framework of the European Network for Cell Imaging and Tracking Expertise (ENCITE) the In-vivo-NMR laboratory at the Max-Planck-Institute for Neurological Research (DE) invited to a 3-day hands-on workshop on November 7-9, 2012, kindly supported by the companies Miltenyi Biotec, Viscover and Medres. The workshop was dedicated to elucidate the techniques and methods necessary for MRI based cell tracking with a focus on neuroimaging.
Cell imaging and tracking: now and the future Promising methods developed to play a central role in tomorrow’s medicine
Cell imaging and tracking: now and the future Promising methods developed to pla …
Vienna, Austria, November 12, 2012 – The European Network for Cell Imaging and Tracking Expertise (ENCITE) held its final workshop on cell imaging and tracking at the Leiden University Medical Centre/NL, on November 5, 2012, attracting over 100 participants. In addressing the questions “What are the clinical needs for imaging and improved disease diagnosis?” and “What are the best tools for translation to clinic?” ENCITE has achieved promising advances, some

All 4 Releases


More Releases for Nijmegen

Ferumoxtran, the iron-based investigational MRI contrast agent of SPL Medical B. …
Nijmegen, The Netherlands, 26.05.2025 - SPL Medical B.V. announced today further results of the pivotal phase III study PROSTAPROGRESS (EudraCT 2018-004310-18), aiming to assess the diagnostic accuracy of Ferumoxtran enhanced Magnetic Resonance Imaging (MRI) for lymph node detection in prostate cancer patients. Patients with known prostate cancer with intermediate to high risk of lymph node metastases without prior treatment were enrolled in the trial. The multicentric prospective PROSTAPROGRESS study has not
Ferumoxtran, the iron-based investigational MRI contrast agent of SPL Medical B. …
Nijmegen, The Netherlands, 25.02.2025 - SPL Medical B.V. announced today the headline results of the pivotal phase III study PROSTAPROGRESS (EudraCT 2018-004310-18), aiming to assess the diagnostic accuracy of Ferumoxtran enhanced Magnetic Resonance Imaging (MRI) for lymph node detection in prostate cancer patients. Ferumoxtran is an Ultrasmall Superparamagnetic Particle of Iron Oxide (USPIO). It does not contain Gadolinium but is based on iron, a physiologically required metal. The dosage applied, 2.6
SPL Medical has entered into an Agreement with NanoEcho for supply and applicati …
Nijmegen, The Netherlands, 27.02.2024 - The business agreement, signed today by SPL Medical and NanoEcho, is a comprehensive contract. The agreement grants NanoEcho exclusivity regarding the supply of ferumoxtran (iron oxide-based nanoparticles) for use in magnetomotive ultrasound. For the clinical effectiveness of the NanoEcho system, the choice of nanoparticles is of crucial im-portance. Ferumoxtran is chosen based on its unique ability to spread in the lymphatic system and differentiate between diseased
SPL Medical announces achievement of next major clinical development milestone f …
Nijmegen, The Netherlands, 02.08.2023 - SPL medical has its proprietary iron-based nano-particle Ferrotran® (Ferumoxtran) product and platform in clinical Phase III. The pivotal trial named PROSTAPROGRESS has now reached the next major milestone by inclusion of over 75% of the patients into this trial. Major academic centers in The Netherlands, Belgium, Germany and Switzerland are contributing constantly. With the PROSTAPROGRESS trial, SPL will verify the superior efficacy and state-of-the-art safety of Ferrotran®,
SPL Medical announces achievement of major Phase III clini-cal development miles …
Nijmegen, The Netherlands, 14.12.2022 - SPL medical has its proprietary iron-based nano-particle Ferrotran® (Ferumoxtran) product and platform in clinical Phase III. The pivotal trial named PROSTAPROGRESS has now reached a major milestone by inclusion of more than 50 % of the planned patient group into this trial. Major academic centres in The Netherlands, Belgium, Germany and Switzerland are contributing constantly. With the PROSTAPROGRESS trial, SPL will verify the superior efficacy and state-of-the-art
SPL Medical announces collaboration with NanoEcho for application of Ferrotran® …
Nijmegen, The Netherlands, 28.09.2022 - SPL medical and NanoEcho have signed a Letter of Intent and initiated a cooperation on regulatory partnership and supply for SPL medical proprietary iron-based nanoparticle Ferrotran® (Ferumoxtran) product and platform. Initially NanoEcho is aiming for market approval for the detection of lymph node metastases in rectal cancer patients. In NanoEcho's method for diagnostics of rectal cancer lymph node metastases, modern ultrasound technology is used together